Reducing residual risk in secondary prevention of cardiovascular disease

Circulation

Volumn 125, Issue 16, 2012, Pages 1958-1960

  Stone, Neil J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

cardiovascular diseases; Editorials; risk; statins

Indexed keywords

ATORVASTATIN; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR RISK; CHRONIC DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; STROKE;

ANTICHOLESTEREMIC AGENTS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PYRROLES;

EID: 84860115121     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.101782     Document Type: Editorial

References (17)

1. Brown MS, Goldstein JL. Heart attacks: gone with the century? Science. 1996;272:629. (Pubitemid 26152774)
2. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
3. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1678.
4. Grundy SM. Promise of low density lipoprotein lowering therapy for primary and secondary prevention. Circulation. 2008;117:569-573.
5. Mora S, Wenger NK, DeMicco DA, Breazna A, Boekholdt SM, Arsenault BJ, Deedwania P, Kastelein JJP, Waters DD. Determinants of residual risk in secondary prevention patients treated with high-versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation. 2012;125:1979-1987.
6. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352: 1425-1435. (Pubitemid 40471450)
7. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011;58:2432-2446.
8. Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendörfer A, Beere PA, Watson DJ, Downs JR, de Cani JS. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101: 477-484. (Pubitemid 30080860)
9. Superko HR. Statins Personalized. Med Clin North Am. 2012;96: 123-139.
10. Wenger NK, Lewis SJ, Welty FK, Herrington DM, Bittner V; TNT Steering Committee and Investigators. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Heart. 2008;94:434-439. (Pubitemid 351444674)
11. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462-467. (Pubitemid 34787477)
12. US Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs http://www.fda.gov/ Drugs/DrugSafety/ucm293101.htm. Accessed March 19, 2012.
13. Maningat P, Breslow JL. Needed: pragmatic clinical for statin-intolerant patients. N Engl J Med. 2011;365:2250-2251.
14. Sanz G, Fuster V, Guzmán L, Guglietta A, Arnáiz JA, Martínez F, Sarria A, Roncaglioni MC, Taubert K. The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug: study design and objectives. Am Heart J. 2011;2: 811-817.e1.
15. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
16. Scanu AM, Hinman J. Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels. Lipids. 2002;7:439-444. (Pubitemid 34535306)
17. Cornier MA, Marshall JA, Hill JO, Maahs DM, Eckel RH. Prevention of overweight/obesity as a strategy to optimize cardiovascular health. Circulation. 2011;124:840-850.